Pfizer's Clinical Pipeline Sparks Analyst Reassessment

Guggenheim lifts Pfizer's price target to $36, citing positive Phase 3 prostate cancer data and a promising pipeline asset. The firm advises rejecting a mini-tender offer.

Guggenheim Securities has revised its outlook for pharmaceutical giant Pfizer, lifting its price target from $35 to $36. This adjustment comes despite a challenging market environment for the company. According to analyst Vamil Divan, the move is grounded in tangible progress within Pfizer's late-stage clinical development portfolio rather than speculative optimism.

Financial Reporting and Strategic Moves

Investors are looking ahead to May 5, 2026, when Pfizer is scheduled to release its first-quarter financial results for 2026. A conference call is set for 4:00 PM Central European Summer Time. Market participants will scrutinize the revenue trajectory and assess the financial impact of the company's ongoing cost-reduction initiatives.

In a separate corporate development, an unsolicited mini-tender offer has emerged. Tutanota LLC has proposed to purchase up to one million shares of Pfizer at a price of $32 per share. On March 20, Pfizer's board formally recommended that shareholders reject this offer. The tender is currently set to expire on April 13, 2026, though its terms state it will be extended until the stock trades above the offering price.

Oncology Advancements Drive Valuation

The most significant catalysts for the reassessment originate from Pfizer's oncology division. On March 19, the company announced positive topline results from its Phase 3 TALAPRO-3 trial. This study evaluated the combination of Talzenna and Xtandi in patients with metastatic hormone-sensitive prostate cancer harboring HRR mutations. The trial successfully met its primary endpoint, demonstrating a statistically significant improvement in radiographic progression-free survival.

Further attention is focused on another late-stage asset, Mevrometostat, currently in the Phase 3 MEVPRO-1 study. Guggenheim assigns a 75% probability of success to this program, with topline data anticipated in the second half of 2026. The analyst's risk-adjusted sales forecast for Mevrometostat stands at approximately $2.0 billion, notably exceeding the broader market consensus estimate of $1.6 billion. Should the trial prove successful, Divan's discounted cash flow model suggests a potential share value of $37.